is tirzepatide glp 1 Systemic effects of dually activating GLP-1 and GIP Microdosing Tirzepatide Program | No

2023: On August 2, 2023 , the first GLP-1 RA drug lawsuit was filed by Jaclyn Bjorklund, a 44-year-old woman from Louisiana, against Novo Nordisk, the manufacturer of Ozempic, alleging her gastroparesis is the result of her taking the medication

Some patients report mild nausea or abdominal discomfort from glutathione alone

Its good to see studies like this - when you have clear numbers, its easier to talk with patients without relying on just trust us. The risks are always there, but what matters is understanding their scale, not imagining the worst

Additionally, individual results may vary, and further research is needed to fully understand the long-term effects and optimal usage of these peptides